84165-41-3

Upstream product

• 148-24-3 8-quinolinol 
• 70-11-1 α-bromoacetophenone 
• 182413-16-7 8-(2-oxopropoxy)quinoline 

Downstream Products

• 1414937-99-7 2,4-bis(4-methoxyphenoxy)-1,5-diphenylpentane-1,5-dione 
• 1335121-85-1 2-oxo-2-phenyl-1-(quinolin-8-yloxy)ethyl acetate 

Relevant academic research and scientific papers

Facile preparation of tetrahydro-5H-pyrido[1,2,3-de]-1,4-benzoxazines via reductive cyclization of 2-(8-quinolinyloxy)ethanones and their antioxidant activity

Pd/C-catalyzed reductive cyclization of 1-aryl-2-(8-quinolinyloxy)ethanones opens a facile access to the title compounds in good yields. The scope of this reductive cyclization is explored and the antioxidant activities of the products are studied.

8-Methoxyquinoline based turn-on metal fluoroionophores

Novel turn-on fluoroionophores 2 and 3 based on highly fluorescent 8-methoxyquinoline were developed in which a sequential singlet-singlet energy transfer, ISC, and triplet-triplet energy transfer occurred leading to a fluorescence 'off' state. They showe

Synthesis of 8-quinolinyl ethers under microwave irradiation

A simple rapid and efficient procedure for the synthesis of 8-quinolinyl ethers via microwave irradiation is reported.

α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation

The present inventors have discovered three classes of novel α-methylene-γ-butyrolactones with excellent antiplatelet activity. As a result of intensive studies, it has been found that compounds represented by the formula I-III are potent inhibitors of platelet aggregation. STR1 For the formula I, R1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C1 -C4) alkyl, (C1 -C4) alkoxy, phenyl, nitro, amino. For the formula II, R1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C1 -C4) alkyl, (C1 -C4) alkoxy, phenyl, nitro, amino; R2 represents hydrogen, halide, (C1 -C4) alkyl, phenyl, nitro, amino; R3 represents hydrogen, halide, (C1 -C4) alkyl, phenyl, nitro, amino. For the formula III, R1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C1 -C4) alkyl, (C1 -C4) alkoxy, phenyl, nitro, amino; R4 represents hydrogen, hydroxy, (C1 -C4) alkyl. The present invention also provides a cost-efficient method for the preparation of formula I-III. Formula I-III may be administered orally or parenterly with an inert diluent or with a pharmaceutically acceptable carrier in the treatment or the prevention of cardiovascular disease.

Antiplatelet α-methylidene-γ-butyrolactones: Synthesis and evaluation of quinoline, flavone, and xanthone derivatives

As a continuation of our previous studies on the synthesis and antiplatelet activity of coumarin derivatives of α-methylidene-γ-butyrolactones, certain quinoline, flavone, and xanthone derivatives were synthesized and evaluated for antiplatelet activity against thrombin (Thr)-, arachidonic acid (AA)-, collagen (Col)-, and platelet-activating factor (PAF)-induced aggregation in washed rabbit platelets. These compounds were synthesized from quinolin-8-ol, flavon-7-ol, and xanthon-3-ol, respectively, via alkylation and Reformatsky-type condensation. By the comparison with coumarin α-methylidene-γ-butyrolactone 3a, flavone and xanthone derivatives, 3b and 3c, respectively, are more selective in which only AA- and collagen-induced aggregation are strongly inhibited. Most of the quinoline derivatives (9a-e) exbibited broad-spectrum antiplatelet activities.